Archives
-
ATRX Loss Sensitizes High-Grade Glioma to RTK Inhibitors
2026-09-28
Pladevall-Morera and colleagues identified ATRX deficiency as a context associated with increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. The study also shows that combining RTK inhibition with temozolomide produces pronounced toxicity in ATRX-deficient models, supporting ATRX status as a useful variable for interpreting targeted-therapy responses.
-
Deltamethrin, Ferroptosis, and Offspring Memory
2026-09-28
A rat study links maternal deltamethrin exposure during pregnancy and lactation to impaired hippocampal learning and memory in male offspring, with evidence implicating p53-associated ferroptosis and disrupted calcium signaling. Its combination of behavioral testing, tissue measurements, and inhibitor-based cell experiments provides a mechanistic framework while leaving important questions about causality, sex differences, and human relevance open.
-
Y-27632 Dihydrochloride for Assay Reliability
2026-09-27
A practical guide to using Y-27632 dihydrochloride (SKU A3008) in cell viability, proliferation, and cytoskeletal studies. It explains assay interpretation, experimental controls, handling, and how to assess a ROCK inhibitor without overstating what the available evidence shows.
-
Remimazolam, Hippocampal HIF-1α, and POCD
2026-09-26
In an aged-mouse surgery model, remimazolam improved cognitive performance and reduced hippocampal neuronal injury alongside lower HIF-1α expression and fewer apoptotic cells. YC-1 produced a similar pattern, supporting a link between HIF-1α signaling and the protective effects observed, although the findings do not establish that this pathway is the only mechanism involved.
-
Niclosamide Workflows for Cancer Research
2026-09-25
Build a mechanism-led Niclosamide workflow that separates STAT3 pathway changes from growth inhibition and cell killing. A staged dose-and-time design helps researchers choose the right readouts for apoptosis, cell-cycle arrest, and overall response.
-
MK-1775: Making Checkpoint Biology Translational
2026-09-25
MK-1775 offers a defined way to interrogate Wee1-dependent control of mitotic entry and the G2 DNA damage checkpoint. For translational researchers, the key is to connect target engagement to distinct measures of growth arrest and cell death, then test whether checkpoint abrogation creates a reproducible vulnerability in p53-deficient models. This article outlines an evidence-led strategy for designing that chain of experiments and interpreting its limits.
-
Mouse Tissue Lysis Kit K1038: Genotyping Guide
2026-09-24
The Mouse Tissue Lysis Kit (K1038) prepares mouse tissue lysates for direct use as PCR templates, reducing the need for a separate DNA extraction step in genotyping workflows. It is intended for scientific research, not diagnostic or medical testing, and the dossier does not provide sample amounts or digestion conditions; consult the current kit instructions for those parameters.
-
1-myristoylglycerophosphocholine in Fibrosis Assays
2026-09-24
Use 1-myristoylglycerophosphocholine (14:0 Lyso-PC) as a defined lipid perturbation to test fibroblast responses, epithelial-to-fibroblast signaling, and smooth muscle pharmacology. This practical guide pairs a staged concentration workflow with controls and troubleshooting, while distinguishing the reference study’s findings about LysoPCs as a class from evidence specific to this molecular species.
-
GRK Subtypes Shape M1 Receptor Signaling Bias
2026-09-23
Using BRET-based interaction measurements, the study shows that GRK subtypes differ in their association with M1 receptors and that their relative interaction efficiencies correlate with the balance between G-protein and β-arrestin2 signaling. Its analysis also finds that BQCA can produce a stand-alone interaction signal and shift acetylcholine concentration–effect curves leftward, offering a mechanistic framework for studying M1 receptor pharmacology.
-
Breast Adenomyoepithelioma Organoids: Study Insights
2026-09-23
Luo and colleagues reported the first patient-derived organoid model established from a breast adenomyoepithelioma, a rare biphasic tumor with poorly defined biology. The model retained the tumor DNA signature and showed measurable, though reduced, responses to paclitaxel and doxorubicin, creating a foundation for disease modeling and treatment studies.
-
Precision PCR for Environmentally Driven Neurogenetics
2026-09-22
Translational neurogenetics depends on more than a compelling biological model: it also requires sequence-accurate, reproducible measurement. This thought-leadership analysis connects pheromone-driven neurodegeneration in C. elegans with the strategic use of HyperFusion™ high-fidelity DNA polymerase for demanding cloning, genotyping, and sequencing workflows.
-
HyperPFU™ high-fidelity DNA polymerase Guide
2026-09-22
HyperPFU™ high-fidelity DNA polymerase is a proofreading DNA polymerase for accurate amplification of long, GC-rich, inhibitor-containing, or otherwise difficult templates. It produces blunt-ended PCR products for cloning and sequencing workflows, but it is not the appropriate choice when a protocol requires 3′-A overhangs or sticky ends.
-
Pifithrin-α: p53 Inhibitor Workflow Guide
2026-09-21
Pifithrin-α enables causal testing of p53 signaling in apoptosis, ferroptosis, DNA-damage responses, and neuronal toxicology. This workflow translates a recent deltamethrin study into practical assay design, formulation controls, and troubleshooting steps for reproducible p53 pathway experiments.
-
Direct Mouse Genotyping Kit Plus for Lineage Studies
2026-09-21
The Direct Mouse Genotyping Kit Plus compresses tissue lysis, template preparation, and endpoint PCR into a practical workflow for colony decisions and research-model validation. Its purification-free format and PCR master mix with dye reagents are especially useful when lineage-tracing, transgene, or knockout cohorts must be screened consistently before complex immunology experiments.
-
Bobcat339 in DNA Methylation Research
2026-09-20
Bobcat339 is a cytosine structure-based TET enzyme inhibitor for testing how TET1/2 activity affects DNA methylation, transcription, and cell-state phenotypes. This workflow connects biochemical inhibition with the UHRF1–super-enhancer–TGM2 pathway reported in senile osteoporosis, while emphasizing controls that distinguish epigenetic effects from toxicity.